N,N-dimethyltryptamine (DMT), a strong psychodysleptic drug, has been found in higher plants, shamanic hallucinogenic beverages, and the urine of schizophrenic patients. The aim of this work was to gain better knowledge on the relationship between this drug and hallucinogenic processes by studying DMT behavior in comparison with tryptamine. Methods: 131 I-labeled DMT and tryptamine were injected into rabbits. g-Camera and biodistribution studies were performed. Brain uptake, plasma clearance, and renal excretion were assessed for each indolealkylamine. Results: DMT and tryptamine showed different behavior when brain uptake, residence time, and excretion were compared. Labeled DMT entered the brain 10 s after injection, crossed the blood-brain barrier, and bound to receptors; then it was partially renally excreted. It was detected in urine within 24 h after injection and remained in the brain, even after urine excretion ceased; up to 0.1% of the injected dose was detected at 7 d after injection in the olfactory bulb. In contrast, tryptamine was rapidly taken up in the brain and fully excreted 10 min after injection. Conclusion: To our knowledge, this is the first demonstration that exogenous DMT remains in the brain for at least 7 d after injection. Although labeled DMT and tryptamine behave as agonists for at least 5-hydroxytryptamine 2A receptor, 5-hydroxytryptamine 2C receptor, trace amine-associated receptor, and s-1 putative receptor targets, binding to the latter can explain the different behavior of labeled DMT and tryptamine in the brain. The persistence in the brain can be further explained on the basis that DMT and other N,N-dialkyltryptamines are transporter substrates for both the plasma membrane serotonin transporter and the vesicle monoamine transporter 2. Furthermore, storage in vesicles prevents DMT degradation by monoamine oxidase. At high concentrations, DMT is taken up by the serotonin transporter and further stored in vesicles by the vesicle monoamine transporter 2, to be released under appropriate stimuli. Moreover, the 131 I-labeling proved to be a useful tool to perform long-term in vivo studies. Incont inuation of our research on labeled compounds, such as phenethylamines, tryptamines, and harmines and native Amazonian N,N-dimethyltryptamine (DMT)-containing beverages such as ayahuasca (1-3) (also called ayahoasca and hoasca tea), we now report the in vivo behavior of DMT and tryptamine.DMT (Fig. 1) is a psychodysleptic compound that has been found in a variety of higher plants (4,5) and organisms (6), brain and other tissues of mammals and humans (6,7), and the urine of schizophrenic patients (2,8-10).As a hallucinogen, DMT was reported as a direct postsynaptic agonist at 5-hydroxytryptamine 2A (5-HT 2A ) receptors and a partial agonist at 5-hydroxytryptamine 2C (5-HT 2C ) receptors (11). Recently, biochemical, physiologic, and behavioral experiments demonstrated that DMT is an endogenous agonist at s-1 receptors (s-1Rs) (12); the hypothetical signaling scheme triggered by this binding ha...
Dimethylglyoxime (DMG) labelled with 99mTc is here presented as a renal imaging agent. The behaviour of this complex was analysed at different pH by means of UV spectral data and using DMG‐calcium chloride as a reference complex. Biokinetic data were evaluated in two biological models, Sprague‐Dawley rats and Didelphis albiventris argentine opossum. Biodistribution in rats demonstrated fast and specific renal excretion. Time‐activity vabues over both kidneys could be quantified for this complex. Renographic studies led to mean time‐to maximum values on twelve assays of 2.0 ± 0.1 min and a mean relative function of 53.0 ± 2.3 and 47.0 ± 3.2 for right and left kidneys, respectively. 99mTc‐DMG showed specificity for the renal excretion pathway and therefore Seems to be a very useful radiopharmaceutical for renal function studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.